MX2018004257A - Antagonista de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos. - Google Patents
Antagonista de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos.Info
- Publication number
- MX2018004257A MX2018004257A MX2018004257A MX2018004257A MX2018004257A MX 2018004257 A MX2018004257 A MX 2018004257A MX 2018004257 A MX2018004257 A MX 2018004257A MX 2018004257 A MX2018004257 A MX 2018004257A MX 2018004257 A MX2018004257 A MX 2018004257A
- Authority
- MX
- Mexico
- Prior art keywords
- nr2b antagonists
- formula
- selective nr2b
- selective
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3309DE2015 | 2015-10-14 | ||
| PCT/US2016/056716 WO2017066368A1 (en) | 2015-10-14 | 2016-10-13 | Selective nr2b antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018004257A true MX2018004257A (es) | 2018-05-16 |
Family
ID=57208377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018004257A MX2018004257A (es) | 2015-10-14 | 2016-10-13 | Antagonista de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10501451B2 (2) |
| EP (1) | EP3362447B1 (2) |
| JP (1) | JP6843853B2 (2) |
| KR (1) | KR20180064507A (2) |
| CN (1) | CN108368101B (2) |
| AU (1) | AU2016340239A1 (2) |
| BR (1) | BR112018007181A2 (2) |
| CA (1) | CA3001894A1 (2) |
| EA (1) | EA201890764A1 (2) |
| ES (1) | ES2822830T3 (2) |
| IL (1) | IL258611A (2) |
| MX (1) | MX2018004257A (2) |
| WO (1) | WO2017066368A1 (2) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6938485B2 (ja) * | 2015-10-14 | 2021-09-22 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 選択的ｎｒ２ｂアンタゴニスト |
| CN112888684B (zh) * | 2018-10-17 | 2023-10-10 | 勃林格殷格翰国际有限公司 | 4-嘧啶-5-基甲基-吗啉衍生物及其作为药物的用途 |
| MY205127A (en) * | 2018-10-17 | 2024-10-03 | Boehringer Ingelheim Int | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament |
| JP7093469B2 (ja) * | 2018-10-17 | 2022-06-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ４－ピリジニルメチル－モルホリン誘導体および医薬としてのその使用 |
| CN113906033B (zh) | 2019-06-04 | 2024-04-02 | 勃林格殷格翰国际有限公司 | 咪唑并吡嗪衍生物及其作为药剂的用途 |
| MX2023006567A (es) * | 2020-12-04 | 2023-06-16 | Novartis Ag | Regimen de dosificacion para un nam del receptor nr2b-nmda para el tratamiento de la depresion. |
| CN113620896A (zh) * | 2021-08-31 | 2021-11-09 | 青岛科技大学 | 2-(2-氯苯基)甲基-4,4-二甲基-3-异恶唑酮的制备方法 |
| CN116063200A (zh) * | 2022-12-12 | 2023-05-05 | 华南理工大学 | 一种异噁唑啉宠物用杀虫剂氟雷拉纳中间体及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| US7022728B2 (en) | 2001-03-09 | 2006-04-04 | Abbott Laboratories | Benzimidazoles that are useful in treating male sexual dysfunction |
| JPWO2003035641A1 (ja) | 2001-10-22 | 2005-02-10 | 塩野義製薬株式会社 | 新規カルバモイルピロリドン誘導体 |
| DE602004015610D1 (de) | 2003-06-04 | 2008-09-18 | Merck & Co Inc | 3-fluoro-piperidine als nmda/nr2b antagonisten |
| MXPA06003748A (es) | 2003-10-08 | 2006-06-14 | Pfizer | Compuestos de lactama condensada. |
| JPWO2005097782A1 (ja) * | 2004-04-07 | 2007-08-16 | 協和醗酵工業株式会社 | ピペリジン誘導体 |
| WO2006137465A1 (ja) * | 2005-06-24 | 2006-12-28 | Shionogi & Co., Ltd. | 含窒素複素環誘導体 |
| EP2520567A3 (en) | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| KR20100045983A (ko) | 2007-06-29 | 2010-05-04 | 에모리 유니버시티 | 신경보호를 위한 ｎｍｄａ 수용체 길항물질 |
| JP2009067784A (ja) * | 2007-08-21 | 2009-04-02 | Shionogi & Co Ltd | 環式基で置換された含窒素複素環誘導体を含有する鎮痛剤 |
| CN105037492A (zh) * | 2010-02-11 | 2015-11-11 | 西北大学 | 二级结构稳定化的nmda受体调节剂及其用途 |
| US9187506B2 (en) | 2014-01-09 | 2015-11-17 | Bristol-Myers Squibb Company | (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
| US9221796B2 (en) * | 2014-01-09 | 2015-12-29 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
-
2016
- 2016-10-13 ES ES16787974T patent/ES2822830T3/es active Active
- 2016-10-13 US US15/767,385 patent/US10501451B2/en active Active
- 2016-10-13 AU AU2016340239A patent/AU2016340239A1/en not_active Abandoned
- 2016-10-13 WO PCT/US2016/056716 patent/WO2017066368A1/en not_active Ceased
- 2016-10-13 CN CN201680073103.8A patent/CN108368101B/zh active Active
- 2016-10-13 EA EA201890764A patent/EA201890764A1/ru unknown
- 2016-10-13 KR KR1020187013128A patent/KR20180064507A/ko active Pending
- 2016-10-13 CA CA3001894A patent/CA3001894A1/en not_active Abandoned
- 2016-10-13 BR BR112018007181A patent/BR112018007181A2/pt not_active Application Discontinuation
- 2016-10-13 MX MX2018004257A patent/MX2018004257A/es unknown
- 2016-10-13 EP EP16787974.1A patent/EP3362447B1/en active Active
- 2016-10-13 JP JP2018519276A patent/JP6843853B2/ja not_active Expired - Fee Related
-
2018
- 2018-04-10 IL IL258611A patent/IL258611A/en unknown
-
2019
- 2019-12-09 US US16/707,382 patent/US10954225B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20180312495A1 (en) | 2018-11-01 |
| EP3362447A1 (en) | 2018-08-22 |
| CA3001894A1 (en) | 2017-04-20 |
| EP3362447B1 (en) | 2020-08-26 |
| JP6843853B2 (ja) | 2021-03-17 |
| EA201890764A1 (ru) | 2018-09-28 |
| IL258611A (en) | 2018-06-28 |
| CN108368101B (zh) | 2022-03-15 |
| WO2017066368A1 (en) | 2017-04-20 |
| US10954225B2 (en) | 2021-03-23 |
| ES2822830T3 (es) | 2021-05-05 |
| KR20180064507A (ko) | 2018-06-14 |
| US10501451B2 (en) | 2019-12-10 |
| CN108368101A (zh) | 2018-08-03 |
| BR112018007181A2 (pt) | 2018-10-16 |
| JP2018530582A (ja) | 2018-10-18 |
| US20200115370A1 (en) | 2020-04-16 |
| AU2016340239A1 (en) | 2018-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018004257A (es) | Antagonista de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos. | |
| CY1121675T1 (el) | Διαμορφωτες υποδοχεων nmdα σπeipο-λακταμης και χρησεις αυτων | |
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| MX2021009830A (es) | Metodos para el tratamiento de trastornos del movimiento involuntario anormal. | |
| MX379110B (es) | Derivados de azaspiro como antagonistas de trpm8. | |
| EA201992474A3 (ru) | Агонисты 5ht для лечения нарушений | |
| TN2016000263A1 (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| MY194104A (en) | Azabenzimidazoles and their use as ampa receptor modulators | |
| TW201613859A (en) | Analogs of PRIDOPIDINE, their preparation and use | |
| MX2017014192A (es) | Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa. | |
| MX2020011668A (es) | Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales. | |
| EA033197B1 (ru) | Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b | |
| NZ736055A (en) | Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators | |
| MX2017013877A (es) | Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa. | |
| TW201713341A (en) | Compositions and methods of treating a neurodegenerative disease | |
| MX2016011105A (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos. | |
| MX2016005759A (es) | Derivados de piridina sustituidos, utiles como inhibidores de glucogeno sintasa cinasa 3 (gsk-3). | |
| MX2017002775A (es) | Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b. | |
| UY35947A (es) | Compuestos antagonistas selectivos de n-metil-d-aspartato (nmda) subtipo nr2b y composiciones que los contienen | |
| PH12015502477A1 (en) | Synthesis of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2,6-dione | |
| PH12016501483A1 (en) | P-substituted asymmetric ureas and medical uses thereof | |
| NZ732704A (en) | Quinoline carboxamides for use in the treatment of leukemia | |
| NZ730816A (en) | Quinoline carboxamides for use in the treatment of multiple myeloma | |
| MX369451B (es) | Formas cristalinas de compuestos basados en 1, 8- naftiridin-4(h)-ona particulares y su uso en el tratamiento de ansiedad y condiciones relacionadas. | |
| PH12016501625A1 (en) | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists |